VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection

被引:423
作者
Storkebaum, E [1 ]
Lambrechts, D [1 ]
Carmeliet, P [1 ]
机构
[1] Catholic Univ Louvain VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium
关键词
D O I
10.1002/bies.20092
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Both blood vessels and nerves are guided to their target. Vascular endothelial growth factor (VEGF)A is a key signal in the induction of vessel growth (a process termed angiogenesis). Though initial studies, now a decade ago, indicated that VEGF is an endothelial cell-specific factor, more recent findings revealed that VEGF also has direct effects on neural cells. Genetic studies showed that mice with reduced VEGF levels develop adult-onset motor neuron degeneration, reminiscent of the human neurodegenerative disorder amyotrophic lateral sclerosis (AILS). Additional genetic studies confirmed that VEGF is a modifier of motor neuron degeneration in humans and in SOD1(G93A) mice-a model of ALS. Reduced VEGF levels may promote motor neuron degeneration by limiting neural tissue perfusion and VEGF-dependent neuroprotection. VEGF also affects neuron death after acute spinal cord or cerebral ischemia, and has also been implicated in other neurological disorders such as diabetic and ischemic neuropathy, nerve regeneration, Parkinson's disease, Alzheimer's disease and multiple sclerosis. These findings have raised growing interest in assessing the therapeutic potential of VEGF for neurodegenerative disorders. (C) 2004 Wiley Periodicals, Inc.
引用
收藏
页码:943 / 954
页数:12
相关论文
共 112 条
[1]   Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy [J].
Acsadi, G ;
Anguelov, RA ;
Yang, HB ;
Toth, G ;
Thomas, R ;
Jani, A ;
Wang, YY ;
Ianakova, E ;
Mohammad, S ;
Lewis, RA ;
Shy, ME .
HUMAN GENE THERAPY, 2002, 13 (09) :1047-1059
[2]   Neurodegeneration: a failure of neuroregeneration? [J].
Armstrong, RJE ;
Barker, RA .
LANCET, 2001, 358 (9288) :1174-1176
[3]   Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 [J].
Autiero, M ;
Waltenberger, J ;
Communi, D ;
Kranz, A ;
Moons, L ;
Lambrechts, D ;
Kroll, J ;
Plaisance, S ;
De Mol, M ;
Bono, F ;
Kliche, S ;
Fellbrich, G ;
Ballmer-Hofer, K ;
Maglione, D ;
Mayr-Beyrle, U ;
Dewerchin, M ;
Dombrowski, S ;
Stanimirovic, D ;
Van Hummelen, P ;
Dehio, C ;
Hicklin, DJ ;
Persico, G ;
Herbert, JM ;
Communi, D ;
Shibuya, M ;
Collen, D ;
Conway, EM ;
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (07) :936-943
[4]   Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1G93A G1H mouse model of familial amyotrophic lateral sclerosis [J].
Azari, MF ;
Lopes, EC ;
Stubna, C ;
Turner, BJ ;
Zang, DW ;
Nicola, NA ;
Kurek, JB ;
Cheema, SS .
BRAIN RESEARCH, 2003, 982 (01) :92-97
[5]   Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling [J].
Beck, H ;
Acker, T ;
Püschel, AW ;
Fujisawa, H ;
Carmeliet, P ;
Plate, KH .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (04) :339-350
[6]   VEGF165 therapy exacerbates secondary damage following spinal cord injury [J].
Benton, RL ;
Whittemore, SR .
NEUROCHEMICAL RESEARCH, 2003, 28 (11) :1693-1703
[7]   A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis [J].
Borasio, GD ;
Robberecht, W ;
Leigh, PN ;
Emile, J ;
Guiloff, RJ ;
Jerusalem, F ;
Silani, V ;
Vos, PE ;
Wokke, JHJ ;
Dobbins, T .
NEUROLOGY, 1998, 51 (02) :583-586
[8]   A dose-dependent facilitation and inhibition of peripheral nerve regeneration by brain-derived neurotrophic factor [J].
Boyd, JG ;
Gordon, T .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 15 (04) :613-626
[9]   Effect of age on cerebral blood flow: Measurement with ungated two-dimensional phase-contrast MR angiography in 250 adults [J].
Buijs, PC ;
Krabbe-Hartkamp, MJ ;
Bakker, CJG ;
de Lange, EE ;
Ramos, LMP ;
Breteler, MMB ;
Mali, WPTM .
RADIOLOGY, 1998, 209 (03) :667-674
[10]   Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions [J].
Carmeliet, P ;
Moons, L ;
Luttun, A ;
Vincenti, V ;
Compernolle, V ;
De Mol, M ;
Wu, Y ;
Bon, F ;
Devy, L ;
Beck, H ;
Scholz, D ;
Acker, T ;
DiPalma, T ;
Dewerchin, M ;
Noel, A ;
Stalmans, I ;
Barra, A ;
Blacher, S ;
Vandendriessche, T ;
Ponten, A ;
Eriksson, U ;
Plate, KH ;
Foidart, JM ;
Schaper, W ;
Charnock-Jones, DS ;
Hicklin, DJ ;
Herbert, JM ;
Collen, D ;
Persico, MG .
NATURE MEDICINE, 2001, 7 (05) :575-583